Akira Science develops programmable, bioresorbable biomaterials designed specifically for soft tissue repair, with its lead product AkiMed™ engineered to degrade in sync with natural tissue healing. The company's platform combines novel chemistry with 3D-printable, tissue-mimicking scaffolds that provide temporary structural support before safely resorbing, addressing a gap left by legacy polymers repurposed from sutures and orthopedic implants.
Funding
$4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
For over 70 years, soft tissue repair has relied on absorbable biomaterials originally designed for sutures, bone fixation, or drug delivery—not for the mechanical and biological demands of soft tissue. Legacy polymers degrade into acidic by-products that can cause inflammation, resorb over timelines out of sync with tissue healing (e.g., PCL taking over 48 months), and lack the flexibility and tissue-like architecture needed for effective integration.
Solution
Akira Science has developed AkiMed™, a family of bioresorbable biomaterials engineered from first principles specifically for soft tissue regeneration. The platform combines novel chemistry with tissue-like architecture to mimic the mechanical properties of soft tissue, offering programmable degradation rates of 6–24 months that align with natural healing timelines. AkiMed™ is 3D-printable and thermally stable up to 300°C, enabling advanced manufacturing of porous scaffolds that support tissue integration and vascularization while degrading safely without harmful by-products. The lead product, AkiMed™ Breast Scaffold, is designed for one-step reconstruction during lumpectomy surgery, preserving breast shape and volume while guiding the body to heal itself.
Target Audience
Primary customers are medical device companies and clinical researchers developing soft tissue repair solutions, as well as breast surgeons seeking improved reconstruction options for lumpectomy patients. The platform also targets applications in injectable fillers, wound care, drug release, and resorbable surgical devices.
Features
- Bioresorbable polymer platform with programmable degradation rates (6–24 months) tailored to soft tissue repair timelines
- 3D-printable material (filament diameter 1.75 mm, thermal stable >300°C) compatible with advanced and conventional polymer processing
- Porous scaffold architecture designed to mimic soft tissue mechanics, promoting cell-material interactions and vascularization
- Available in multiple formats: technical-grade pellets, 3D-printing filament, microspheres, and 3D scaffolds
- AkiMed™ Breast Scaffold: IP-protected, standardized sizes, validated in-vitro and in-vivo for reconstruction after lumpectomy
- Customizable material properties from molecular level to final product, including tailored degradation rates and mechanical characteristics